Prelude Therapeutics Inc (PRLD)
4.07
+0.03
(+0.74%)
USD |
NASDAQ |
Apr 26, 16:00
4.01
-0.06
(-1.47%)
After-Hours: 20:00
Prelude Therapeutics Shareholders Equity (Quarterly): 237.09M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 237.09M |
| September 30, 2023 | 238.26M |
| June 30, 2023 | 262.06M |
| March 31, 2023 | 175.30M |
| December 31, 2022 | 195.44M |
| September 30, 2022 | 217.41M |
| June 30, 2022 | 240.84M |
| March 31, 2022 | 261.81M |
| Date | Value |
|---|---|
| December 31, 2021 | 285.90M |
| September 30, 2021 | 311.24M |
| June 30, 2021 | 334.36M |
| March 31, 2021 | 356.57M |
| December 31, 2020 | 212.18M |
| September 30, 2020 | 228.31M |
| June 30, 2020 | -69.31M |
| December 31, 2019 | -49.41M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-69.31M
Minimum
Jun 2020
356.57M
Maximum
Mar 2021
214.88M
Average
237.67M
Median
Shareholders Equity (Quarterly) Benchmarks
| CEL-SCI Corp | 12.65M |
| AIM ImmunoTech Inc | 10.23M |
| IGC Pharma Inc | 9.053M |
| NovaBay Pharmaceuticals Inc | 3.314M |
| Protalix BioTherapeutics Inc | 33.57M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 277.66M |
| Total Liabilities (Quarterly) | 40.58M |